GSK plc reported its block listing interim review on May 13, 2024, detailing unallotted securities for the GlaxoSmithKline equity plans, with notable numbers including a balance of 115,518 for the 2017 Deferred Annual Bonus Plan and 995,257 for the 2022 Share Save Plan.